Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAWID M SARWARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1649698630
CMS profile
4226112
Location
ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$6,680.72

252 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,194.10 237
Long term medical supply or device loan $1,096.70 11
Education $389.92 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $1,468.46 26
Astellas Pharma US Inc $399.41 7
Merck Sharp & Dohme LLC $307.71 13
Eisai Inc. $295.52 12
PFIZER INC. $286.46 18
Incyte Corporation $271.17 12
Daiichi Sankyo Inc. $247.68 9
ABBVIE INC. $242.44 16
Janssen Biotech, Inc. $217.75 11
Takeda Pharmaceuticals U.S.A., Inc. $193.75 8
SOBI, INC $186.56 13
AstraZeneca Pharmaceuticals LP $176.63 7
GlaxoSmithKline, LLC. $146.25 10
BeiGene USA, Inc. $136.23 5
Gilead Sciences, Inc. $132.73 6
Lilly USA, LLC $129.32 5
Exelixis Inc. $114.08 3
ARRAY BIOPHARMA INC $101.43 4
PUMA BIOTECHNOLOGY, INC. $100.64 4
TAIHO ONCOLOGY, INC. $99.13 4
Alexion Pharmaceuticals, Inc. $96.08 3
Rigel Pharmaceuticals, Inc. $92.51 4
Deciphera Pharmaceuticals Inc. $91.33 4
EMD Serono, Inc. $84.22 3
PharmaEssentia USA Corporation $80.15 3
Blueprint Medicines Corporation $77.89 3
Celgene Corporation $71.92 3
GENZYME CORPORATION $67.76 2
Bayer Healthcare Pharmaceuticals Inc. $66.54 3
E.R. Squibb & Sons, L.L.C. $61.66 4
SpringWorks Therapeutics, Inc. $51.98 2
Karyopharm Therapeutics Inc. $48.65 2
Sumitomo Pharma America, Inc. $44.27 2
Mirati Therapeutics, Inc. $43.90 2
RECORDATI_RARE_DISEASES_INC. $42.50 2
Regeneron Healthcare Solutions, Inc. $36.92 1
Genmab U.S., Inc. $32.17 1
Aveo Pharmaceuticals, Inc. $30.18 1
Octapharma USA, Inc. $29.75 1
Stemline Therapeutics Inc. $28.39 1
Tolmar, Inc. $25.14 1
Fennec Pharmaceuticals, Inc. $24.47 1
Adaptive Biotechnologies Corporation $23.69 1
Boehringer Ingelheim Pharmaceuticals, Inc. $22.13 1
Coherus Biosciences Inc. $21.90 1
ImmunoGen, Inc. $20.76 1
Pharmacosmos Therapeutics Inc. $20.70 1
Kyowa Kirin, Inc. $20.59 1
Tempus AI, Inc $20.57 1
Ipsen Biopharmaceuticals, Inc $19.39 1
PROGENICS PHARMACEUTICALS, INC. $14.71 1
Agios Pharmaceuticals, Inc. $14.55 1

Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAWID M SARWARI

NPI 1649698630 · CMS profile ID 4226112

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649698630?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649698630?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649698630?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 252 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1649698630?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

252 matching records · $6,680.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 252 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 252.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $34.5408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110769523 CMS
Janssen Biotech, Inc. $28.5408/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078285989 CMS
Astellas Pharma US Inc $28.8408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139372321 CMS
BeiGene USA, Inc. $29.0608/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120856553 CMS
SpringWorks Therapeutics, Inc. $27.2707/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085807885 CMS
ABBVIE INC. $0.9707/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106022601 CMS
ABBVIE INC. $17.6407/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106022603 CMS
BeiGene USA, Inc. $20.1507/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120856555 CMS
Merck Sharp & Dohme LLC $30.0707/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811095 CMS
PUMA BIOTECHNOLOGY, INC. $29.1407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113848514 CMS
ARRAY BIOPHARMA INC $23.2007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131774375 CMS
Blueprint Medicines Corporation $34.3907/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147449974 CMS
Janssen Biotech, Inc. $1.6407/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078286171 CMS
Janssen Biotech, Inc. $30.7607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078285917 CMS
Merck Sharp & Dohme LLC $23.0107/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141906679 CMS
PUMA BIOTECHNOLOGY, INC. $23.7007/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113849300 CMS
Karyopharm Therapeutics Inc. $28.0307/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145534564 CMS
Novartis Pharmaceuticals Corporation $99.7007/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087182119 CMS
GlaxoSmithKline, LLC. $3.7007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116709735 CMS
Novartis Pharmaceuticals Corporation $10.1707/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087182059 CMS
Rigel Pharmaceuticals, Inc. $21.3107/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145204250 CMS
GENZYME CORPORATION $37.7807/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139595120 CMS
Gilead Sciences, Inc. $18.6707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133806089 CMS
Novartis Pharmaceuticals Corporation $33.3607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087182057 CMS
Eisai Inc. $23.9007/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110769519 CMS
Merck Sharp & Dohme LLC $22.9807/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811089 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.4506/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144966669 CMS
ABBVIE INC. $19.2706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106022599 CMS
ABBVIE INC. $28.8706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106022597 CMS
Astellas Pharma US Inc $99.9506/25/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139340304 CMS
Astellas Pharma US Inc $89.9906/25/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139340318 CMS
Merck Sharp & Dohme LLC $27.4206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811087 CMS
PFIZER INC. $13.4406/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131700536 CMS
BeiGene USA, Inc. $31.6106/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120856557 CMS
Incyte Corporation $27.0206/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141275140 CMS
Blueprint Medicines Corporation $15.5706/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147449968 CMS
AstraZeneca Pharmaceuticals LP $28.0606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104451566 CMS
Incyte Corporation $22.6306/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141199699 CMS
Pharmacosmos Therapeutics Inc. $20.7006/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154825787 CMS
Incyte Corporation $23.7406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141173331 CMS
PFIZER INC. $26.8906/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131334971 CMS
Novartis Pharmaceuticals Corporation $99.7006/13/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087182069 CMS
PFIZER INC. $22.5806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131334967 CMS
GlaxoSmithKline, LLC. $3.0706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116365421 CMS
Novartis Pharmaceuticals Corporation $11.5306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087182055 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.2706/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144966667 CMS
Incyte Corporation $26.5406/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141201371 CMS
AstraZeneca Pharmaceuticals LP $32.7106/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104481124 CMS
Rigel Pharmaceuticals, Inc. $19.9306/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145202808 CMS
Eisai Inc. $14.6306/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110769525 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $245.89 2
PY2020 $3,704.99 64
PY2021 $7,521.17 161
PY2022 $4,395.48 214
PY2023 $5,386.30 248
PY2024 $6,680.72 252
PY2025 $6,044.07 247

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,254.58 38
PY2024 Principal investigator $21,904.46 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $40.89 12/19/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612688
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731074
Principal investigator 1 Hoffmann-La Roche Limited $6,812.10 12/01/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612692
Principal investigator 1 Hoffmann-La Roche Limited $300.00 11/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612684
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731072
Principal investigator 1 Hoffmann-La Roche Limited $35.90 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612664
Principal investigator 1 Hoffmann-La Roche Limited $39.92 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612672
Principal investigator 1 Hoffmann-La Roche Limited $36.58 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612652
Principal investigator 1 Hoffmann-La Roche Limited $39.50 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612676
Principal investigator 1 Hoffmann-La Roche Limited $472.50 10/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612680
Principal investigator 1 Hoffmann-La Roche Limited $212.50 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612644
Principal investigator 1 Hoffmann-La Roche Limited $7,352.10 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612660
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731070
Principal investigator 1 Hoffmann-La Roche Limited $2,112.75 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612640
Principal investigator 1 Hoffmann-La Roche Limited $11,194.20 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612648
Principal investigator 1 Hoffmann-La Roche Limited $250.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612655
Principal investigator 1 Hoffmann-La Roche Limited $108.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612669
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612602
Principal investigator 1 Hoffmann-La Roche Limited $445.50 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612635
Principal investigator 1 Hoffmann-La Roche Limited $45.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612617
Principal investigator 1 Hoffmann-La Roche Limited $37.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612625
Principal investigator 1 Hoffmann-La Roche Limited $30.85 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612631
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612606
Principal investigator 1 Hoffmann-La Roche Limited $41.88 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612628
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731050
Principal investigator 1 Hoffmann-La Roche Limited $12.94 08/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612621
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731048
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731054
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731056
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731058
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731060
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731062
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731064
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731066
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731068
Principal investigator 1 Hoffmann-La Roche Limited $29.82 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612609
Principal investigator 1 Hoffmann-La Roche Limited $25.87 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612613
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731052